COMMUNIQUÉS West-GlobeNewswire

Clover Health Announces Chelsea Clinton to Step Down from Board Following Eight Years of Service
31/10/2025
WILMINGTON, Del., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced that Chelsea Clinton, the longest-serving member of its [...]
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/10/2025
CANTON, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (the “Company”) (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of [...]
Edesa Biotech Announces Upcoming Conference Schedule
31/10/2025
TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today [...]
Cellectis publiera ses résultats financiers du troisième trimestre le 7 novembre 2025
31/10/2025
NEW YORK, 31 oct. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des [...]
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
31/10/2025
Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers (DFU) patients Preparing to submit [...]
Cellectis to Report Third Quarter Financial Results on November 7, 2025
31/10/2025
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
31/10/2025
MALVERN, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/10/2025
BOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, the Compensation [...]
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November
31/10/2025
TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor [...]
Protext Mobility, Inc. (OTC: TXTM) Announces CEO Statement Following Removal of Caveat Emptor Designation
31/10/2025
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM) (“TXTM”), an emerging biotechnology company pioneering advancements in plant-based therapeutics, today released an official statement from [...]
Fagron’s share buy-back program: Weekly update
31/10/2025
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 31 October 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 27 October 2025 through 31 October 2025, Fagron purchased [...]
Veru to Present Two Abstracts at ObesityWeek 2025
31/10/2025
MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
NewGen Enters Into an Innovative Digital Assets Purchase Agreement with White Lion to Acquire up to 600,000 Solana Tokens Valued at Over $110 Million
31/10/2025
BANGKOK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through [...]
Disc Medicine to Participate in Upcoming Investor Conferences
31/10/2025
WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
31/10/2025
BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and [...]
Prenetics Bolsters Bitcoin Treasury with Strategic Acquisition of 100 Bitcoin, IM8 Reaches $100M ARR
31/10/2025
Additional Bitcoin Acquisition Follows Immediately on $44 Million Equity Offering Company now holds a total of 378 BTC (valued at ~$41 Million) CHARLOTTE, N.C., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited [...]
IntoCell and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC Technologies
31/10/2025
DAEJEON, South Korea and NORTH BETHESDA, Md., Oct. 31, 2025 (GLOBE NEWSWIRE) -- IntoCell Inc. (KOSDAQ: 287840), a biotechnology company developing next-generation payload and linker technologies for antibody–drug [...]
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
31/10/2025
Faster initial remission and response, persistent benefit over six months SALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision [...]
Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
31/10/2025
Correcting press release issued under same heading: Date in body text corrected to "November 6, 2025" as in headline. COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage [...]

Pages